Population pharmacokinetic/pharmacodynamic analysis of AK111, an IL-17A monoclonal antibody, in subjects with moderate-to-severe plaque psoriasis

Qian Li1, Ju Qiao2†, Hongzhong Jin2, Benchao Chen3, Zhimei He3, Guoqin Wang3, Xiang Ni3, Max Wang3, Michelle Xia3, Baiyong Li3, Rui Chen1* and Pei Hu1*

1Clinical Pharmacology Research Center, Peking Union Medical College Hospital, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK and PD Investigation for Innovative Drugs, Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China, 2Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China, 3Akeso Biopharma, Inc, Zhongshan, China

AK111 is an innovative IL-17A antibody, presenting high affinity to IL-17A and showing similar pharmacokinetic (PK) characteristics to those of typical immunoglobulin (Ig) G1 antibodies. To optimize the dosage regimen for phase 2/3 clinical trials, PK and pharmacodynamics (PD) of AK111 were first characterized in Chinese moderate-to-severe plaque psoriasis patients in a phase 1b study. AK111 PK serum sample and Psoriasis Area and Severity Index (PASI) score data were collected from 48 moderate-to-severe psoriasis patients in this study. Non-linear mixed-effects modeling was used for the population PK/PD analysis. A one-compartment model with a first-order absorption and a first-order elimination best described the PK behavior of AK111. The apparent systemic clearance was 0.182 L/day, and the central volume was 6.65 L. The exposure–response relationship was characterized using an indirect response model. The pharmacological effect of AK111 was described in the form of inhibiting the formation of psoriatic plaque, whereas placebo was quantified in the form of promoting the degradation of psoriatic skin lesions. The maximum effect of drug effect (Imax) and placebo effect (PLBmax) was 1 and 0.429, respectively. The rate constant for psoriatic plaque production (K in) was 0.474 PASI/day and psoriatic plaque loss (Kout) was 0.024 day−1. The body surface area (BSA) affected by psoriasis was identified as a significant covariate on Kout. The simulation results confirmed that all of the predicted PASI90 response rates at week 12 were higher than 60% at 150 and 300 mg dose levels with different regimens and could reach higher than 80% at week 24. We hope this first PK/PD study of AK111 in Chinese moderate-to-severe plaque psoriasis patients will be of help in the further clinical development of
Introduction

Psoriasis is a chronic immune-mediated autoimmune skin disease. Approximately 125 million people worldwide have psoriasis, which is associated with a number of co-morbidities including psoriatic arthritis, cardiometabolic diseases, and depression (Armstrong and Read 2020). Plaque psoriasis is the most common type of psoriasis, accounting for more than 80% of the psoriasis cases. Plaque psoriasis is characterized by patches of erythema covered in a silvery-white scale, resulting from rapid hyperproliferation and dysregulated differentiation of epidermal keratinocytes (Armstrong and Read 2020; Gisondi et al., 2020). The pathogenesis of psoriasis is complex and not fully elucidated. It is reported to originate from an interplay of genetic, environmental, infectious, and lifestyle factors (Girolomoni et al., 2017). The dysregulated crosstalk between keratinocytes and immune cells contributes to the pathogenesis of psoriasis (Gao et al., 2020). Much evidence suggests that the interleukin (IL)-17/IL-23 axis is a major player in the pathogenesis of psoriasis (Di Cesare et al., 2009), and several biologics targeting the IL-17/IL-23 axis were approved for the treatment of psoriatic diseases (Bai et al., 2019).

AK111 is a humanized IgG1 monoclonal antibody (mAb) that specifically binds IL-17A with high affinity, which is currently in the early stages of clinical research. Cell level in vitro pharmacological activity showed that AK111 can block pro-inflammatory cytokine secretion mediated by the IL-17/IL-17 receptor signaling pathway. An in vivo efficacy study demonstrated that AK111 could inhibit epidermal thickening, keratinocyte hyperproliferation in mice models of psoriasis (in-house data). A randomized, double-blind, placebo-controlled phase I b clinical trial of AK111 injection in patients with a moderate-to-severe plaque psoriasis had recently been accomplished. The primary endpoint was to evaluate the safety, tolerability, and pharmacokinetic (PK) profiles of a subcutaneous injection of AK111, and the secondary endpoint was to evaluate its clinical efficacy and immunogenicity.

A reasonable dosing regimen design was one of the key considerations for the next stage’s clinical trial design, establishing exposure–effect relationships based on early PK and clinical efficacy data that can help inform the dose selection. The Psoriasis Area and Severity Index (PASI) is a measure of the average redness, thickness, and scaliness of the lesions weighted by the area of involvement which lies in the range between 0 (no disease) and 72 (maximal disease). It is the current gold standard for the assessment of extensive psoriasis and was employed as the scoring system to assess the efficacy of AK111 in its early phase (Zurauskas et al., 2020). Clinical improvement was measured by the percent change in the PASI score from baseline (Medical Advisory Secretariat, 2009). These time courses of PK and PASI score data collected from the phase I b study permit an assessment of the exposure–response relationship of AK111 in moderate-to-severe plaque psoriasis.

Population PK-pharmacodynamic (PD) modeling, which links the concentration time course (including variation across dosing intervals) to the time course of the pharmacodynamic response, provides quantitative information to predict the drug exposure–response relationship (Tuntland et al., 2014; Overgaard et al., 2015). It is now well considered that the population PK-PD modeling and simulation are effective tools to determine the optimal dosage and administration frequency of a new drug (Belissant and Giudicelli, 2001). The overall aim of this study was to develop a population PK/PD model of AK111 to perform a covariate analysis to explain interpatient PK/PD variability. Simulations of different dosing regimens are subsequently performed via this model in order to provide information for the dose regimen selection of the next stage of clinical development.

Materials and methods

Study design

The phase I b study was a single-center, randomized, double-blind, placebo-controlled clinical trial, which was conducted in Chinese moderate-to-severe plaque psoriasis patients to observe the pharmacokinetic profile, safety, and efficacy of AK111. The study was conducted in accordance with the Declaration of Helsinki and approved by the independent ethics committee of Peking Union Medical College Hospital (Beijing, China). All patients were fully informed and signed written informed consent forms prior to their enrollment.

Forty-eight patients with moderate-to-severe psoriasis were recruited in accordance with the inclusion and exclusion criteria. They were assigned to four dose cohorts (75, 150, 300, or 450 mg). In each cohort, 12 patients were randomized in a ratio of 3:1 to receive AK111 (N = 9) and matching placebo (N = 3), respectively. All injections were given subcutaneously at
weeks 0, 1, 4, and 8. The serum samples were collected at pre-
dose (D1), 2, 4, 8, 15, 22, 29, 36, 57, 85, 113, and 141 days, and
postdose-6h at day 1, day 8, day 29, and day 57 to obtain free
AK111 concentration. Serum concentrations of AK111 were
measured by sandwich enzyme-linked immunosorbent assay
(ELISA), the method was fully validated with the lower limit
of quantification (LLOQ) being 0.05 ug/mL. PASI scores were
evaluated at the time of pretreatment on D8, D15, D29, D57,
D85, D113, and D141. Participants who withdraw prematurely
were asked to complete serum sample collection and the PASI
score assessment at the point of early termination.

Population pharmacokinetic/
pharmacodynamics model building

The population PK/PD model was developed using non-
linear mixed-effects modeling [NONMEM v7.3.0, Pirana® v2.9.7,
PsN (Perl-speaks-NONMEM) v5.0.0] and visualized using R
(v4.0.3). A sequential modeling strategy was applied and
individual post-hoc Bayesian estimates of the developed PK
model were added to the PD dataset. First-order conditional
estimation–extension with the interaction (FOCE-I) method was
used to estimate the population PK/PD model parameters.

An exploratory graphical analysis was conducted by plotting
individual and mean profiles to identify possible starting models
and facilitate the identification of potential outliers. One- and
two-compartment disposition models were evaluated for the PK,
as well as several different absorption models, including first- and
zero-order absorption models. Based on the mechanism of
action, an indirect response model was chosen as a PD model
for the PASI score. Outliers were considered the absolute value
of conditional weighted residual (CWRES) greater than 6. They
were excluded from our data if these outliers had a negative
influence on the convergence and/or made poor estimation
precision of parameters, otherwise they will be removed.

An exponential model was used to describe the
interindividual variability (IIV):

\[ \theta_i = \theta \cdot \exp(\eta_i), \]  

where \( \theta_i \) represents the parameter estimate for the ith individual,
\( \theta \) is the population estimate for parameter \( \theta \), and \( \exp(\eta_i) \) is
the interindividual random deviation of \( \theta_i \) from \( \theta \). \( \eta_i \) was
assumed to be normally distributed with mean zero and variance
of \( \sigma^2_i \). As for the residual error model, both additive
and multiplicative with the proportional error model were evaluated.

Several variables like age, gender, weight, disease duration,
baseline PASI score, body surface area (BSA) involvement, and
use of biologics, were tested as potential covariates. A covariate
model building was a stepwise process consisting of a forward
and a backward selection procedure, in which continuous
covariates were described using the power function and
categorical covariates were modeled by an exponential
function, see Eqs 2, 3. During the forward inclusion step, a
covariate was considered significant and included in the basic
model if the OFV decreased by more than 6.635 at the statistical
level of \( p \) value of <0.01 (2 distribution with 1 degree of
freedom). All of the significant covariates were then
incorporated into the basic model to construct a full model.
Next, backward elimination was used to exclude covariates from
the full model with an increase in the OFV of < 10.828 with a
\( p \) value of < 0.001 (2 distribution with 1 degree of freedom).

\[ \theta_i = \theta \cdot \left( \frac{\text{COV}_i}{\text{COV}_\text{median}} \right)^{\delta_i}, \]  

\[ \theta_i = \theta \cdot (e)^{\delta_i \text{cov}}. \]  

Model comparison were based on the objective function
value (OFV) using the likelihood ratio test (LRT) for nested
models and the Akaike Information Criterion (AIC) for non-
nested models. The accuracy of model parameter estimation
and the complexity of the model are also factors to be considered
when selecting the final model.

Model evaluation and simulation

The models were evaluated using internal validation
techniques. Goodness-of-fit (GOF) plots were used to evaluate
the general parameter precision, including conditional weighted
residuals (CWRES) versus time, CWRES versus population
prediction (PRED), dependent variable (DV) versus PRED or
individual population prediction (IPRED). Prediction-corrected
visual predictive checks (pvVPC) with 1,000 simulated datasets
were also used to assess the predictive performance of the model.
In pcVPC, the variability coming from variations in independent
variables within a single bin is removed by normalizing the
observed and simulated dependent variable based on the
typical population prediction (Bergstrand et al., 2011). Results
from the pcVPC were assessed by a graphical comparison of the
medians and 90% prediction intervals calculated at each bin from
the predicted–corrected simulated concentration compared to
the observed concentration from the original dataset. A non-
parametric bootstrap was performed from which the precision in
the parameter estimates were evaluated by the calculation of
standard errors.

The final population PK/PD model was used to simulate the
PASI score of AK111 after different dosing regimens using a
Monte Carlo simulation approach. The model was run with
1,000 Monte Carlo simulations using typical values and
interpatient variability estimated from the final PK/PD model,
the covariates of the virtual patient still leveraged those of the
phase IIb dataset. The PASI75 and PASI90 (75% and 90%
reductions in the PASI score from the baseline) response rates
were calculated using the PASI score predicted by the model.
Results

Population characteristics

In total, 48 moderate-to-severe plaque psoriasis patients were enrolled, wherein 12 patients received placebo and 36 patients received AK111 injection. Baseline demographics and subject characteristics of the 48 patients are summarized in Table 1. One subject in the 450 mg cohort was not included in the analysis due to delayed administration, and 47 patients were available for the PK/PD analysis. Finally, a total of 516 PK samples from patients treated with AK111 and 344 PASI scores from patients treated with AK111 and placebo were used for PK/PD modeling, and no outliers were found in our PK/PD data. Concentrations below the LLOQ (<6%) were only distributed at time zero and were excluded according to the M1 method recommended by Keizer et al. during PK model building (Keizer et al., 2015). All PASI score data were included in the final PK/PD model building.

Population pharmacokinetic/pharmacodynamics model building

According to the AIC value and the GOF plots, the selected final proposed PK/PD model structure is shown in Figure 1. A one-compartment with a first-order absorption and a first-order elimination model best described the PK behavior of AK111. No covariates were found to be associated with the PK parameters. The PASI score was fitted well through an indirect response model with both the drug effect and placebo effect, and BSA was identified as a significant covariate on $K_{out}$. The model assumed that baseline PASI was at the steady state prior to dosing and was governed by a zero-order formation rate constant ($K_{in}$) and a first-order degradation rate constant ($K_{out}$) for the psoriatic plaques.

TABLE 1 Demographic and baseline characteristics (mean ± SD).

| Characteristic    | 75 mg  | 150 mg | 300 mg | 450 mg | Placebo | Total |
|-------------------|--------|--------|--------|--------|---------|-------|
| Number of subjects| 9      | 9      | 9      | 9      | 12      | 48    |
| Age (years)       | 33.4 ± 6.9 | 41.7 ± 11.2 | 39.0 ± 7.9 | 38.3 ± 9.1 | 38.7 ± 8.4 | 38.2 ± 8.9 |
| Height (cm)       | 166.9 ± 6.5 | 163.8 ± 6.1 | 170.0 ± 8.3 | 169.9 ± 9.2 | 167.7 ± 9.3 | 168 ± 8.1 |
| Weight (kg)       | 65.7 ± 10.1 | 64.2 ± 8.7 | 71.0 ± 8.8 | 67.3 ± 10.3 | 69.2 ± 11.3 | 67.5 ± 10.0 |
| BMI (kg/m2)       | 23.5 ± 3.0 | 23.9 ± 2.4 | 24.5 ± 1.4 | 23.3 ± 3.0 | 24.5 ± 2.9 | 24 ± 2.6 |
| Disease duration (years) | 14.8 ± 5.4 | 16.3 ± 5.0 | 18.3 ± 5.7 | 12.8 ± 6.3 | 15.8 ± 4.9 | 15.7 ± 5.4 |
| BSA (%)           | 30.6 ± 12.3 | 30.8 ± 15.2 | 38.7 ± 16.4 | 36.5 ± 18.7 | 30.8 ± 11.2 | 33.3 ± 14.7 |
| Baseline PASI     | 191 ± 4.7 | 169 ± 3.8 | 22.8 ± 6.4 | 22.8 ± 7.4 | 18.5 ± 3.4 | 20 ± 5.6 |
| Use of biologicals, n (%) | 0 (0.0%) | 2 (22.2%) | 1 (11.1%) | 1 (11.1%) | 0 (0.0%) | 4 (8.5%) |

FIGURE 1 Schematic overview of the final population PK/PD model. SC: subcutaneous injection; $A_{depot}$: AK111 amounts in absorption depot; $A_1$: AK111 amounts in central compartment; $K_a$: subcutaneous absorption rate constant; $CL$: clearance from the central compartment $K_{in}$: zero-order formation rate constant for the psoriatic plaques; $K_{out}$: first-order degradation rate constant for the psoriatic plaques; $I_{max}$: maximum inhibition effect on plaque forming rate constant; $IC_{50}$: concentration at half-maximal inhibition; $PLB_{max}$: maximum effect of placebo effect; $K_{plb}$: rate constant of the reduction from the maximum placebo effect.
plagues. AK111 in the central compartment inhibited Kin to the inhibited plaque-forming process. And, placebo reduced the PASI score by increasing the degradation rate constant (Kout) for the psoriatic plaques. All PK/PD model parameters are summarized in Table 2. The mathematical representation of the final model is provided in Eqs 4–8.

Model evaluation

Figures 2–5 show the GOF plots of the final population PK/PD model. Plots of the dependent variable (DV) versus population prediction (PRED) or individual population prediction (IPRED) demonstrated that the final model fits the data well. There were no obvious deviations in the plots of conditionally weighted residuals (CWRES) vs. time or population prediction (PRED). The plots were symmetrically distributed about the zero axis and most points were laid within the acceptable range (~1.96 to 1.96).

The pcVPC method could remove the variability coming from binning across an independent variable by normalizing the observed and simulated dependent variable, while retaining the visual interpretation of the traditional VPC (Bergström et al., 2011). The pcVPC results for the population PK and PK/PD models are shown in Figure 6 and Figure 7. The pcVPC from the population PK model confirmed the robustness of the model stability and PK parameters were estimated with good precision with 90% of the observed values within the 5th and 95th percentiles of the simulated data (Figure 6). One observed concentration at day 22 was significantly higher than the others, resulting in a lower prediction of the 95th percentile of observation. The pvVPC of the PK model also showed a slight underprediction around the 5th percentile of observation after day 113. But they have little impact on the clinical utility of this model because most of the 5th, 50th, and 95th percentiles of prediction were in good agreement with the observed data.

The pcVPC of the final PK/PD model showed that the 50th and 95th percentiles of the prediction-corrected prediction PASI scores were consistent with the 50th and 95th percentiles of observations, even though the 5th percentile was slightly underpredicted (Figure 7). As treatment progresses, the predicted 5th percentile of PASI becomes out of data range (< 0), this is because there was great interindividual variation in the PASI score, especially those time points after 84 days. When the predicted

### Table 2: The estimated value of the PK/PD parameters in the model.

| Parameters (unit) | Definition                                                        | Point estimate | RSE % | Bootstrap of estimates median | Bootstrap of estimates 90%CI | Shrinkage % |
|-------------------|------------------------------------------------------------------|----------------|-------|-------------------------------|-------------------------------|-------------|
| **PK model**      |                                                                  |                |       |                               |                               |             |
| Ka (1/day)        | Subcutaneous absorption rate constant                            | 0.463          | 9.3   | 0.461                         | 0.392–0.534                   | NA          |
| CL (L/day)        | Clearance from the central compartment                           | 0.182          | 7.2   | 0.182                         | 0.159–0.205                   | NA          |
| V (L)             | Volume of the peripheral compartment                              | 6.65           | 7.8   | 6.65                          | 5.77–7.54                     | NA          |
| IV Ka (%)         | Interindividual variability in Ka                                | 50.1           | 13.5  | 48.9                          | 36.6–60.4                     | 5.7         |
| IV CL (%)         | Interindividual variability in CL                                | 42.2           | 12.4  | 41.5                          | 33.0–49.5                     | 0.1         |
| IV V (%)          | Interindividual variability in V                                 | 46.4           | 13.4  | 45.6                          | 35.1–54.6                     | 0.1         |
| σprop             | Proportional error for serum concentration                       | 0.0144         | 9.4   | 0.0146                        | 0.012–0.017                   | 10          |
| σadd              | Additive error for serum concentration                           | 1.48           | 42.4  | 1.372                         | 0.442–2.51                    | 10          |
| **PD model**      |                                                                  |                |       |                               |                               |             |
| Kout (PASI/day)   | First-order rate constant for psoriatic plaque production         | 0.474          | 21.3  | 0.481                         | 0.305–0.643                   | NA          |
| Kass (1/day)      | Zero-order rate constant for psoriatic plaque loss               | 0.024          | 21.5  | 0.025                         | 0.015–0.033                   | NA          |
| Imax              | The maximum effect of drug effect                                | 1 Fixed        | 66.4  | 0.566                         | 0–1.174                       | NA          |
| CIC50 (ug/mL)     | The concentration to achieve 50% Emax                            | 0.52           | 5.90  | 25.2                          | 15.5–27.5                     | 98.8        |
| PLBmax            | The maximum effect of placebo effect                             | 0.429          | 78.2  | 0.394                         | 0–1.056                       | NA          |
| Ksb               | Rate constant of reduction from maximum effect                   | 0 Fixed        | 0     | Fixed                         | NA                            |             |
| BSA               | Covariate about BSA on Kout                                      | −0.572         | −7.68 | −0.573                        | −0.644–0.499                  | NA          |
| IV Kass (%)       | Interindividual variability in Kin                               | 16.0           | 38.7  | 16.8                          | 9.50–25.2                     | 98.8        |
| IV Ksb (%)        | Interindividual variability in Kout                              | 23.3           | 13.8  | 22.2                          | 15.5–27.5                     | 18.3        |
| IV CIC50 (%)      | Interindividual variability in IC50                             | 161.2          | 33.5  | 161.2                         | 67.6–494.6                    | 47.8        |
| IV PLBmax (%)     | Interindividual variability in PLBmax                            | 98.7           | 15.0  | 96.4                          | 64.7–138.2                    | 20.8        |
| σPASI             | Additive error for PASI score                                    | 4.53           | 21.6  | 4.49                          | 2.92–6.13                     | 11.5        |

RSE, relative standard error; CI, confidence interval.
PASI score became near 0, together with high variation and residual errors, this led to 5th percentile of PASI score below zero. They did not impact the clinical utility of this model because the predicted PASI score below zero meant the psoriasis plaque was complete eliminated, the scores were treated as zero when calculating the response rate. Despite these deviations, the
90% prediction interval of the simulated data covered most of the observations. The bootstrap results are also shown in Table 2. The median values from the bootstraps were close to the typical values of parameter estimates of the final model. All the typical parameter values fell within 90% CI of the bootstrap results, which indicated the high stability and precision of the final model.

**Model simulation**

Different dosing regimens of AK111 were simulated using Monte Carlo methods to obtain PASI scores, and the PASI75 and PASI90 response rates were calculated. Figure 8 and Figure 9 shows the comparison time profiles of the PASI75 and PASI90 response rates observed versus model-predicted time profiles stratified by dosage. The values of the PASI75 response rates observed at various time points were almost within 95% prediction intervals in the four dose levels (Figure 8). The predicted PASI90 response rate of 450 mg dose level was lower than the observation after day 29 (Figure 9). The main reason for the underprediction of the PASI90 response rate in these dose levels could be that one subject was excluded due to delayed administration; there were only eight subjects in this cohort. A more detailed explanation can be found in the Discussion.

We then simulated the 150 and 300 mg dose levels with different loading and maintenance dose frequencies: 1) dose at weeks 0, 1, and 4, followed by Q4W or Q6W; 2) dose at weeks 0, 1, 2, 3, and 4, followed by Q4W or Q6W; 3) dose at weeks 0, 2, 4, 6, and 8, followed by Q4W or Q6W; 4) dose at weeks 0, 2, 4, 6, 8, and 10, followed by Q4W or Q6W. The predicted medians of the PASI75 and PASI90 response rates of the eight dosing regimens are showed in Figures 10–13. The simulation results suggested that for each dose level, at the initial phase using different loading dosing regimens, the onset time did not appear to change significantly, this result needs to be verified by sufficient observational data. Compared with Q4W, the administration of Q6W showed similar PASI75 and PASI90 response rates in the maintenance period. At week 12, the predicted median PASI75 response rate in each dose regimen was above 90%, and was close to 100% till week 24 (Figure 10 and Figure 12). All of the PASI90 response rates at week 12 were higher than 60% at 150 and 300 mg dose levels with different regimens, and could reach higher than 80% at week 24 (Figure 13 and Figure 11).

**Discussion**

Population PK and PD modeling of antibodies is instrumental for dosage designing and optimizing throughout the drug development process (Wang et al., 2008). In the present study, a population PK-PD model was established in the Chinese moderate-to-severe plaque psoriasis patients and simulations were performed to guide the AK111 dose selection for phase 2/3 trials.
Although the pathogenesis of psoriasis is still not fully elucidated, molecular and genetic studies have identified the main inflammatory pathways involved in the pathogenesis of psoriasis (Rendon and Schakel 2019). Several mAbs designed to block either specific receptors or soluble mediators of the main pathways were approved for treating psoriasis, including TNF-α, IL-12/23, and IL-17 antibodies (Rodriguez-Fernandez et al., 2022). Secukinumab, ixekizumab, and brodalumab are three anti-IL-17 mAbs which are already available in the market (Mrowietz et al., 2021), AK111 is also targeting IL-17A. Despite the same target site, the PK and PD properties of these molecules are specific. To the best of our knowledge, this is the first study to report the PK and PD properties of AK111 in Chinese moderate-to-severe plaque psoriasis patients.

The PK profile of AK111 was well described by a one-compartment model with first-order absorption. During model building, no target-mediated drug disposition was observed. The data were well fitted by first-order elimination kinetics. A two-compartment model was tried when building the PK model, however, little effect on the improvement of the model was observed, and the estimation accuracy of the parameters was poor and the RSE% values of some parameters were extremely high. The one-compartment model was finally selected considering that the elimination phase of the last administration was not dense sampling and the intercompartmental clearance rate of the two-compartment model may not be well estimated.

Based on the population PK model, the Ka value estimated was low (0.463 day⁻¹). These data suggest that AK111 was slowly absorbed from the injection site following the subcutaneous injection (75–450 mg). With the molecular weight of approximately 150 kDa, the extravascular distribution of AK111 is expected to be very small. The apparent volume of distribution in moderate-to-severe psoriasis patients was low (6.65 L), which was slightly greater than the serum volume. The majority of IgG mAbs cannot be filtered by the kidney. Their elimination occurs via intracellular catabolism, including fluid-phase or receptor-mediated endocytosis (Wang et al., 2008). AK111 showed a slow serum clearance (0.182 L/day) with an average elimination half-life (t1/2) of 25.3 days.

**FIGURE 8**
Comparison of the observed time profiles of PASI75 and PASI90 response rates versus model-predicted time profiles stratified by dose. Observed and predicted PASI75 response rates stratified by dose.
The t1/2 is similar with Secukinumab (a human IgG1 anti-IL-17A antibody), and longer than another IL-17A antibody Ixekizumab \((t_{1/2} = 13 \text{ days})\) (Craig and Warren 2020). The long half-life could support longer dosing intervals, which can improve the adherence of patients from a clinical perspective, especially for chronic diseases.

The most common clinical covariates for mAbs treating psoriasis were body weight and the presence of immunogenicity on CL (Bruin et al., 2017; Rodriguez-Fernandez et al., 2022). For AK111, none of the covariate (age, gender, weight, disease duration, baseline PASI score, and BSA) relationships were identified in the developed population PK model. The reason was the small size of the sample and a narrow range of continuous covariate distributions. In this case, the value of the covariate analysis was limited, and we used a model with no covariates as the final model.

For the clinical study in psoriasis, the PASI score is typically used for the diagnosis and evaluation of psoriatic diseases (Ashcroft et al., 1999). The score combines the extent of involvement and severity of redness, thickness, and scaling from each body region (head, trunk, arms, and legs) to give a score ranging from 0 to 72 with higher scores indicating greater disease severity (Salinger et al., 2014). Based on an exploratory analysis of our data, we observed that most subjects had achieved the greatest reduction in the PASI scores till 12 weeks after the first dose administration with a delay relative to the peak concentration. The indirect response (IDR) modeling approach capable of characterizing the lag in time between time course of pharmacokinetic and pharmacodynamic events, and could explain the formation and elimination of plaque dynamics semi-mechanistically. This semi-mechanistic pharmacokinetic–pharmacodynamic (PK-PD) models in psoriasis have been published for a few biologic compounds based on the PASI score (Zhou et al., 2010; Salinger et al., 2014). We also tested several other models during PD model building, including an effect-compartment model, effect-compartment link indirect response (IDR) model, logistic regression model (considered the PASI75 response as dichotomic variables), Emax model using the rate of the PASI75 response (response rate from 0% to 100%) as the outcome; however, these models either did
not perform better than the IDR model or failed to be established due to limited sample size.

Improvement in the PASI scores was observed in the placebo group. Though the effects were small, they could not be neglected. Thus, the placebo effect was integrated in the model, and the parameters related to placebo were estimated from patients who received placebo. The reported placebo effects either act on formation of the plaques (Salinger et al., 2014) or the degradation of plaques (Tham et al., 2014). In order to avoid a co-mingled drug and placebo effect, we assumed that the placebo reduced the PASI score by increasing the degradation rate constant ($K_{\text{out}}$) for the psoriatic plaques.

The drug-related PD parameter estimates from this model were found to be comparable to those reported for another anti-IL-17A monoclonal antibody (Brodalumab) in patients with moderate-to-severe plaque (Salinger et al., 2014). The $I_{\text{max}}$ was fixed to 1 because the maximal effect could theoretically be a full 100% reduction in the PASI score which can be seen from our PASI score data, this was the same as the results David H. Salinger reported (Salinger et al., 2014). The concentration to achieve 50% $E_{\text{max}}$ ($IC_{50}$) was 0.52 $\mu$g/mL with RSE% was 66.4%, and was not associated with any of the covariates. The higher RSE % was also observed in Brodalumab (49.7%) and Ixekizumab (60.3%) (Salinger et al., 2014; Tham et al., 2014), this is because the subpopulations of the responder and non-responder make the distribution of the post hoc $IC_{50}$ parameter as a bimodal distribution (Zhou et al., 2010; Tham et al., 2014; Pan et al., 2020), but in our study, the sample size was too small to distinguish two subpopulations. $K_{\text{in}}$ and $K_{\text{out}}$ were parameters that related to the disease, the reported $K_{\text{in}}$ was 0.615–0.890 PASI/day, $K_{\text{out}}$ was 0.0313–0.064 day$^{-1}$ (Zhou et al., 2010; Salinger et al., 2014; Tham et al., 2014; Rodriguez-Fernandez et al., 2022). In our study, $K_{\text{in}}$ was 0.474 PASI/day, $K_{\text{out}}$ was 0.024 day$^{-1}$, and both of them were lower than those reported in the literature. The possible reason is that the estimation of these two parameters depends on the baseline PASI score, which is different among patients enrolled in different clinical studies.

The maximum placebo effect ($PLB_{\text{max}}$) was 0.429 with RSE % being 78.2 %, similar to that reported by David H. Salinger (0.439 with 59.5 % SE) (Salinger et al., 2014). Another placebo-
related parameter was the rate constant of reduction from maximum effect (K_plb), the value reported in the literature was 0.046 day$^{-1}$ (with 49.3% SE) (Salinger et al., 2014). During the progress of modeling, the K_plb value estimated in our model was much lower than reported (<10$^{-4}$, data not shown), this indicated that the rate constant of reduction from the maximum effect was negligible, so the K_plb value was fixed to zero in our final model.

Among all covariates analyzed of the influence on PD parameters, we found that BSA was the most influential covariate correlating with K_out, this has not been reported in previous studies. Chuanpu Hu (Hu et al., 2018) reported the body weight effect on K_out in guselkumab exposure–response relationship studies, the difference between our result with Chuanpu Hu may be because we used the PASI score as the outcome to established the relationship between exposure and efficacy in our model, but Chuanpu Hu used the PASI Response Thresholds (Prt) in their model, so the K_out of the two models has different meanings. Finding the source of interindividual variation of IC$_{50}$ is important because its large IIV and different individuals have different treatment outcomes; higher doses may be required for non-responder subpopulations (Tham et al., 2014). Lai-San Tham reported the PASI75 responder status at week 12 as a significant covariate for the EC$_{50}$ parameter (Tham et al., 2014; Rodriguez-Fernandez et al., 2022), some literatures reported that the covariate analysis identified high-sensitivity C-reactive protein (hs-CRP) as a statistically significant covariate for risankizumab EC$_{50}$ (Khatri et al., 2020; Suleiman et al., 2020). In our analysis, the addition of any covariable does not reduce the IIV of this parameter; one possible reason is that the sample of 47 is too small. The effect of covariates on placebo-related parameters has not been reported in previous studies, due to the smaller sample size (n = 12), it is also difficult to explain the interindividual variation in placebo parameters for us.

Different dose regimen simulations based on this population PK/PD model were performed. Based on the observed efficacy of this study, 150 and 300 mg were selected as the candidate dose levels in the next phase II clinical trial, because the curves of mean PASI score over time at both dose levels were close to 450 mg.

**FIGURE 11**
Simulated median PASI75 and PASI90 response rates under different dose regimens using the final population PK/PD model. The PASI90 response rate of 300 mg in eight dosing regimens. Different colors of lines represent the median response rate of different dosing regimens.
and the maximum PASI75 response rates both could reach the maximum of 100% (Figure 8). Psoriasis is a chronic disease that requires long-term management, systemic therapy of plaque psoriasis consisting of the induction phase (usually 12 weeks or 16 weeks) and the maintenance phase (Mrowietz et al., 2011). Our result of observed and predicted response rates showed that there needs to be 12 weeks after administration for the maximal response rate. So, another concern was if the initial phase using loading dosing regimens could allow the patient to achieve maximum efficacy quickly. So, we designed four loading dosing regimens (W1/2/4; W1/2/3/4; W2/4/6/8; and W2/4/6/8/10) to be simulated. To maintain the long-term efficacy of AK111, rational administration frequency needed to be studied. We simulated the dosing frequency for Q4W based on the half-life of AK111 (t1/2 = 25.3 days), a longer dosing interval Q6W was also simulated and compared with Q4W.

The PASI75 and PASI90 response rates of different dosing regimens were calculated based on the PASI score simulated by the final PK/PD model. In the past, the treatment goal of psoriasis was the PASI75 response proposed by the European Consensus Programme (ECP) (Mrowietz, 2012) and FDA also uses PASI75 as a primary efficacy endpoint for new psoriasis drugs. Now, there is an accumulation of evidence in support of the PASI90 response becoming the new therapeutic goal standard based on its better correlation with health-related quality of life (HRQoL) improvement (Puig, 2015). Several models have previously been reported in the literature using categorical scores such as PASI75 as an outcome indicator to establish the population pharmacokinetic–logistic regression model (Hutmacher et al., 2007; Suleiman et al., 2020; Jackson et al., 2021), but their model was based on data from phase III clinical trials with a relatively large sample size. Our study was based on a phase I b trial with a total of 48 patients in four cohorts, the small sample size in each cohort was not sufficient to accurately calculate response rates because the result might be easily influenced by random effects, so we did not use the response rate as the outcome when building the model.

In order to assess the accuracy of the PASI75/95 response rates calculated by simulated PASI scores, we did the visual
predictive check to compare the observed time profiles of the PASI75/90 response rates versus the model-predicted time profiles. The result showed a clear underprediction of the PASI90 response rates after day 30. We think one reason was the change of efficacy from a low dose to high dose was irregular for PASI90, as can be seen in Figure 8, the PASI90 response rate in the 150 mg cohort was higher than the 300 mg cohort at days 85 and 113, which may affect the establishment of the exposure–efficacy relationship in the high-dose group. Another reason is that, one subject in the 450 mg group was excluded due to delayed administration; there were only eight subjects in this group. Due to such a small sample size, whether one subject reached PASI90 might have had a very large influence to the response rate. More data are needed to explain the uncertainty of the model in the PASI90 prediction at high-dose levels. Finally, the simulation results showed the initial phase using different loading–dosing regimens did not appear to change the onset time significantly. Administration of Q6W showed similar PASI75 and PASI90 response rates compared with Q4W in the maintenance period. This needs to be verified by future clinical studies.

The study had some limitations. Firstly, the number of patients was limited as the data were from a phase Ib clinical trials. The large interindividual variability of some parameters might be due to the small sample size. Secondly, the simulation result was based on the typical value and interindividual variability estimated from 47 patients. They did not fully represent the real-world clinical setting. Thirdly, the prediction of PASI90 in the high-dose level was relatively poor. More data from further studies should be integrated to determine a better dose–response relationship.

Conclusion

The population PK/PD model of AK111 was first established in Chinese moderate-to-severe plaque psoriasis patients based on the data of a phase Ib study. The relationship between exposure and PASI score was well described by the population model.
and treatment of psoriasis: A review.

Clinical measures of disease severity and outcome in psoriasis: A critical appraisal of to-date.

Funding

This work was supported by the Clinical Research Fund from Wujieping Medical Foundation (No. 320.6750.19090-12), Golden Bridge Project of Beijing Association for Science and Technology (No. ZZ20047); Drug Development and Application Fund from the Chinese Pharmacological Society (No. 2018DL001); Beijing Key Laboratory (No. Z15110000165061); and Chinese National Major Project for New Drug Innovation (No. 2019ZX0973-4001).

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material; further inquiries can be directed to the corresponding authors.

Ethics statement

The studies involving human participants were reviewed and approved by Peking Union Medical College Hospital. The patients/participants provided their written informed consent to participate in this study.

Author contributions

RC, PH, JQ, and HJ designed and organized the clinical trial. JQ and HJ collected the data. QL analyzed the data and wrote the manuscript. QL, HJ, RC, and PH were involved in the discussion of results. BC, ZH, GW, XN, MW, MX, and BL reviewed and edited the manuscript. All the authors have read and approved the final manuscript.

References

Armstrong, A. W., and Read, C. (2020). Pathophysiology, clinical presentation, and treatment of psoriasis: A review. JAMA 323 (19), 1945–1960. doi:10.1001/jama.2020.4006

Ashcroft, D. M., Wan Po, A. L., Williams, H. C., and Griffiths, C. E. (1999). Clinical measures of disease severity and outcome in psoriasis: A critical appraisal of their quality. Br. J. Dermatol. 141 (2), 185–191. doi:10.1046/j.1365-2133.1999.02963.x

Bai, F., Li, G. G., Liu, Q., Niu, X., Li, R., Ma, H., et al. (2019). Short-term efficacy and safety of IL-17, IL-12/23, and IL-23 inhibitors brodalumab, Secukinumab, tezokizumab, ustekinumab, guselkumab, tidlakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: A systematic review and network meta-analysis of randomized controlled trials. J. Immunol. Res. 2019, 2546161. doi:10.1155/2019/2546161

Bellissant, E., and Giudicelli, J. F. (2001). Pharmacokinetic-pharmacodynamic model for perindopril regional haemodynamic effects in healthy volunteers and in congestive heart failure patients. Br. J. Clin. Pharmacol. 52 (1), 25–33. doi:10.1046/j.0306-5251.2001.01410.x

Bergstrand, M., Hooker, A. C., Wallin, J. E., and Karlsson, M. O. (2011). Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 13 (2), 143–151. doi:10.1208/s12248-011-9255-z

Bruijn, G., Losche, C., Nystrand, J., and Sander, Ø. (2017). Population pharmacokinetic modeling of Secukinumab in patients with moderate to severe psoriasis. J. Clin. Pharmacol. 57 (7), 876–885. doi:10.1002/jcph.876

Craig, S., and Warren, R. B. (2020). Ixekizumab for the treatment of psoriasis: Up-to-date. Expert Opin. Biol. Ther. 20 (6), 549–557. doi:10.1080/14712598.2020.1729736

Di Cesare, A., Di Meglio, P., and Nestle, F. O. (2009). The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J. Invest. Dermatol. 129 (6), 1339–1350. doi:10.1038/jid.2009.59

Gao, J., Guo, J., Nong, Y., Mo, W., Fang, H., Mi, J., et al. (2020). 18β-Glycyrrhetinic acid induces human HaCaT keratinocytes apoptosis through ROS-mediated PI3K-Akt signaling pathway and ameliorates DaQ-induced psoriasis-like skin lesions in mice. BMC Pharmacol. Toxicol. 21 (1), 41. doi:10.1186/s40360-020-00419-0

Girolomoni, G., Strohal, R., Puig, L., Bachelez, H., Barker, J., Boehncke, W. H., et al. (2017). The role of IL-23 and the IL-23/Th17 immune axis in the pathogenesis and treatment of psoriasis. J. Eur. Acad. Dermatol. Venereol. 31 (10), 1616–1626. doi:10.1111/jdv.14433

Gisondi, P., Bellinato, F., Girolomoni, G., and Albanesi, C. (2020). Pathogenesis of chronic plaque psoriasis and its intersection with cardio-metabolic comorbidities. Front. Pharmacol. 11, 117. doi:10.3389/fphar.2020.00117
Hu, C., Yao, Z., Chen, Y., Randazzo, B., Zhang, L., Xu, Z., et al. (2018). A comprehensive evaluation of exposure-response relationships in clinical trials: Application to support guselkumab dose selection for patients with psoriasis. J. Pharmacokinet. Pharmacodyn. 45 (4), 523–535. doi:10.1007/s10928-018-9581-1

Hutmacher, M. M., Nesterov, I., Ludden, T., Zitnik, R., and Banfield, C. (2007). Modeling the exposure-response relationship of etanercept in the treatment of patients with chronic moderate to severe plaque psoriasis. J. Clin. Pharmacol. 47 (2), 238–248. doi:10.1177/0022321006295062

Jackson, K., Chua, L., Velez de Mendizabal, N., Pitou, C., Rodriguez Capriles, C., Paller, A. S., et al. (2021). Population pharmacokinetic and exposure-effect analysis of ixekizumab in pauciarticular patients with moderate-to-severe plaque psoriasis (DXOA-PEDS). Br. J. Clin. Pharmacol. 88 (3), 1074–1086. doi:10.1111/bcp.15034

Keizer, R. I., Jansen, R. S., Rosing, H., Thijssen, B., Beijnen, J. H., Schellens, J. H., et al. (2015). Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses. Pharmacol. Res. Perspect. 3 (2), e00131. doi:10.1002/prp2.1331

Khatri, A., Saleiman, A. A., Polepally, A. R., and Othman, A. A. (2020). Exposure-response relationships for efalizumab in psoriasis patients. Clin. Pharmacol. Ther. 107 (2), 378–387. doi:10.1002/cpt.1594

Medical Advisory Secretariat (2009). Ultraviolet phototherapy management of moderate-to-severe plaque psoriasis: An evidence-based analysis. Ont. Health Technol. Assess. Ser. 9, 1–66.

Mrowietz, U. (2012). Implementing treatment goals for successful long-term management of psoriasis. J. Eur. Acad. Dermatol. Venereol. 26 (2), 12–20. doi:10.1111/j.1468-3083.2011.03436.x

Mrowietz, U., Krabbe, K., Reich, K., Spuls, P., Griffiths, C. E., Nast, A., et al. (2011). Definition of treatment goals for moderate to severe psoriasis: A European consensus. Arch. Dermatol. Res. 303 (1), 1–10. doi:10.1007/s00403-010-1080-1

Mrowietz, U., Warren, R. B., Leonardi, C. L., Saure, D., Petto, H., Hartz, S., et al. (2021). Network meta-analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method. J. Eur. Acad. Dermatol. Venereol. 35 (5), 1161–1175. doi:10.1111/jdv.17130

Overgaard, R. V., Ingwersen, S. H., and Tornoe, C. W. (2015). Establishing good practices for exposure-response analysis of clinical endpoints in drug development. CPT. Pharmacometrics Syst. Pharmacol. 4 (10), 565–575. doi:10.1002/psp4.12015

Pan, S., Tsokos, T., Dand, N., Lonsdale, D. O., Loeff, F. C., Bloem, K., et al. (2020). Using real-world data to guide ustekinumab dosing strategies for psoriasis: A prospective pharmacokinetic-pharmacodynamic study. Clin. Transl. Sci. 13 (2), 400–409. doi:10.1111/cts.12725

Puig, L. (2015). PASI90 response: The new standard in therapeutic efficacy for psoriasis. J. Eur. Acad. Dermatol. Venereol. 29 (4), 643–648. doi:10.1111/jdv.12817

Rendon, A., and Schakel, K. (2019). Psoriasis pathogenesis and treatment. Int. J. Mol. Sci. 20 (6), 1475. doi:10.3390/ijms20061475

Rodriguez-Fernandez, K., Mangas-Sanjuan, V., Merino-Sanjuan, M., Martorell-Calatayud, A., Mateu-Puchades, A., Climente-Marti, M., et al. (2022). Impact of pharmacokinetic and pharmacodynamic properties of monoclonal antibodies in the management of psoriasis. Pharmaceutics 14 (3), 654. doi:10.3390/pharmaceutics14030654

Salinger, D. H., Endres, C. J., Martin, D. A., and Gibbs, M. A. (2014). A semi-mechanism model to characterize the pharmacokinetics and pharmacodynamics of brodalumab in healthy volunteers and subjects with psoriasis in a first-in-human single ascending dose study. Clin. Pharmacol. Drug Dev. 3 (4), 276–283. doi:10.1002/cpdd.103

Saleiman, A. A., Khatri, A., Oberoi, R. K., and Othman, A. A. (2020). Exposure-response relationships for the efficacy and safety of risankizumab in Japanese subjects with psoriasis. Clin. Pharmacokinet. 59 (5), 575–589. doi:10.1007/s40262-019-00829-2

Tham, L. S., Tang, C. C., Choi, S. L., Satterwhite, J. H., Cameron, G. S., Banerjee, S., et al. (2014). Population exposure-response model to support dosing evaluation of secukinumab in patients with chronic plaque psoriasis. J. Clin. Pharmacol. 54 (10), 1117–1124. doi:10.1122/jcph.10023

Tuntland, T., Ethell, B., Kosaka, T., Blasco, F., Zang, R. X., Jain, M., et al. (2014). Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical Research. Front. Pharmacol. 5, 174. doi:10.3389/fphar.2014.00174

Wang, W., Wang, E. Q., and Balhazar, J. P. (2008). Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther. 84 (5), 548–558. doi:10.1038/cpt.2008.170

Zhou, H., Hu, C., Zhu, Y., Lu, M., Liao, S., Yeilding, N., et al. (2010). Population-based exposure-effect modeling of ustekinumab in patients with moderate to severe plaque psoriasis. J. Clin. Pharmacol. 50 (3), 257–267. doi:10.1177/0091270009343695

Zurauskas, M., Barkalifa, R., Alex, A., Marjanovic, M., Spillman, D. R., Jr., Mukherjee, P., et al. (2020). Assessing the severity of psoriasis through multivariate analysis of optical images from non-lesional skin. Sci. Rep. 10 (1), 9154. doi:10.1038/s41598-020-65689-4